The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment
Abstract Background Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer’s disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuropro...
المؤلفون الرئيسيون: | Antonia Keck, Julia-Sophia Scheuermann, Petra Scheerbaum, Elmar Graessel, Kirsten R. Müller-Vahl |
---|---|
التنسيق: | مقال |
اللغة: | English |
منشور في: |
BMC
2025-01-01
|
سلاسل: | BMC Complementary Medicine and Therapies |
الموضوعات: | |
الوصول للمادة أونلاين: | https://doi.org/10.1186/s12906-025-04753-w |
مواد مشابهة
-
Disposition of Cannabidiol Metabolites in Serum and Urine from Healthy Individuals Treated with Pharmaceutical Preparations of Medical Cannabis
حسب: Ana Pilar Pérez-Acevedo, وآخرون
منشور في: (2020-12-01) -
Individualised computerised cognitive training (iCCT) for community-dwelling people with mild cognitive impairment (MCI): results on cognition in the 6-month intervention period of a randomised controlled trial (MCI-CCT study)
حسب: Elmar Graessel, وآخرون
منشور في: (2024-10-01) -
3D Printed Bigel: A Novel Delivery System for Cannabidiol-Rich Hemp Extract
حسب: Anna Gościniak, وآخرون
منشور في: (2024-11-01) -
Cannabis Contaminants Limit Pharmacological Use of Cannabidiol
حسب: Zackary Montoya, وآخرون
منشور في: (2020-09-01) -
El cannabidiol y sus indicaciones en psiquiatría
حسب: Juan Fernando Muñoz Ramírez
منشور في: (2021-03-01)